Effect of adding vildagliptin to start of insulin treatment in combination with metformin in patients with type 2 diabetes - Effect of adding vildagliptin to insulin treatment

niversity Medical Centre Utrecht0 个研究点目标入组 40 人开始时间: 2009年11月11日最近更新: 2012年7月31日

适应症

试验速览

暂无简介。

•- Type 2 diabetes mellitus
•- Failing on oral-glucose-lowering medication: maximum tolerated doses of metformin, and/ or sulphonylurea and/ or TZD
•- Male and female
•- BMI 25-35
•- HbA1c 7.0-9.0 %
•- Age 25-75 y
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•- Pregnant women or women in the fertile period of life without adequate birth-control
•- Type I DM, or secondary form of DM (eg pancreatic injury, prednisone induced)
•- Acute metabolic complications (severe hypoglycaemia, hospital-admission for uncontrolled
•- Keto-acidosis) during the last 6 months
•- Severe cardiac (LVEF < 30%) or hepatic, or renal impairment (creatinine clearance <50 ml/min)

发起方

niversity Medical Centre Utrecht